European independent medical cannabis company, EMMAC Life Sciences Ltd (EMMAC), has announced the acquisition of Rokshaw.
Sunderland-based Rokshaw is a manufacturer of ‘specials’. The acquisition of Rokshaw will enable EMMAC to import medical cannabis into the UK and meet growing market demand.
Rokshaw holds licenses in MHRA Specials Manufacturing, Home Office Controlled drugs schedule 2, and Wholesale dealers authorisation. The company is pursuing additional licenses which would allow greater research into cannabis-based products for medicinal use (CBPMs).
Antonio Costanzo, CEO of EMMAC, commented: “We are delighted to announce the acquisition of Rokshaw today. This investment not only brings with it an immediate revenue stream but also provides EMMAC instant access to the UK medical cannabis market with the opportunity to grow the existing 45 people-strong team into a centre of medical cannabis excellence for the UK. Joining us are the two founders of Rokshaw, Jonathan and Richard Hodgson, who have significant and relevant experience of working in this highly regulated industry as well as a proven track record of delivering high-quality product.”
Jonathan and Richard Hodgson, co-founders of Rokshaw, said: “We are really pleased to have joined EMMAC at this exciting stage of its corporate development as we share its vision of becoming the leading European independent medical cannabis company. We are confident that the team here at Rokshaw can play an important role in EMMAC achieving its goal through the provision of high-quality product and services to patients across the UK, and by unlocking the potential for the medical cannabis market to meet growing clinician and patient demand.”
Rokshaw is EMMAC’s second GMP-certified laboratory, following Medalchemy, the Company’s research and development facility in Spain.